Administering a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed. The combination of vistusertib along with paclitaxel (Taxol) chemotherapy caused tumours of over half of patients with ovarian cancer and over a third with lung… Read more

After more than a century of controversy about the origins of childhood leukaemia, new analysis has revealed the likely cause. Professor Mel Greaves from The Institute of Cancer Research, London, assessed the most comprehensive body of evidence ever collected on acute lymphoblastic leukaemia (ALL) – the most common type of childhood cancer. He compiled more… Read more

Patients who survived cancer years or even decades ago still become fatigued more quickly than people without cancer histories, a new study indicates. In a long-term aging study, cancer survivors reported more fatigue after treadmill tests and, on average, they walked slower than participants who had never had cancer, the scientists found. “The main goal… Read more

Circadian rhythms could hold the key to novel therapies for glioblastoma, the most prevalent type of brain cancer in adults. In research with cell cultures, scientists determined that the timed production of a particular protein associated with tumor proliferation and growth is disrupted in glioblastoma cells. The discovery may lead to a more effective technique… Read more

Chemotherapy for acute myeloid leukemia could be improved by giving patients a drug currently used to treat an unrelated condition, researchers led by a team from Imperial College London have found. Acute myeloid leukaemia (AML) is an aggressive cancer that stops healthy blood cell production. Chemotherapy is the standard treatment, but improvements are needed as… Read more